MLANA and neoplasm: We set a high threshold (3-fold increase from baseline) to define a MART-1-specific immune response, and IMP321-supplemented vaccines stimulated significantly greater and more sustained MART-1 tetramer reactivity than the control group, suggesting that the addition of a vaccine adjuvant such as the IMP321 is essential for boosting anti-tumor immunity.